1998    Ph.D, University of Warwick, UK.

1998 ~ 1999    Postdoctoral fellow, Institute of Information Science, Academia Sinica, Taiwan.
1999 ~ 2000    Cell Works Inc, Baltimore, Maryland, U.S.A.
2001 ~ 2003    Bioinformatics Head & department manager, Biomedical Engineering Center, Industrial Technology Research Center, Taiwan.
2003    Adjunct Assistant Professor, Dept. Biology, National Taiwan Normal University, Taiwan.
2004    Visiting Scientist, Institute of Neuroscience, Queen’s Medical Center, University of Nottingham, UK.
2004 ~ 2009    Bioinformatics Head, Vita Genomics Inc. Taiwan.
2011 ~ 2017    Faculty Scientist, Department of Medical Research, Chang Gung Memorial Hospital, Linko, Taiwan
2017 ~ present    Associate Investigator, Department of Medical Research, Taipei Veterans General Hospital, Taiwan.
2018 ~ present    Adjunct Associate Professor, Institute of Food Safety and Health Risk Assessment, Institute of Biomedical Informatics, National Yang-Ming University, Taiwan

<Research Interests>
1.Human Genomics and its roles in complex diseases and rare diseases.
2.Pediatric brain tumors
3.Liver, viral hepatitis and hepatocellular carcinoma
4.Lung cancer
5.Food and Drug Safety

<Selected Recent Publications>

1. Wang ML, Lin Y, Hou JF, Yang YP, Chien Y, Sun YC, Liang KH, Yang DM, Chang TJ, Wu CH, Kao SY, Hung KF. (2022, Dec). The Omicron variant wave: Where are we now and what are the prospects?. Journal of the Chinese Medical Association, doi: 10.1097/JCMA.0000000000000863. .
2. Huang EY, Chen YK, Ou CP, Chen YT, Chen SF, Huang WJ, Liang KH. (2022, Nov). Oncogenic Roles of Polycomb Repressive Complex 2 in Bladder Cancer and Upper Tract Urothelial Carcinoma.. Biomedicines.
3. Yang DM, Chang TJ, Hung KF, Wang ML, Cheng YF, Chiang SH, Chen MF, Liao YT, Lai WQ, Liang KH. (2022, Oct). Smart healthcare: A prospective future medical approach for COVID-19.. Journal of the Chinese Medical Association, doi: 10.1097/JCMA.0000000000000824.
4. Liang KH, Hung KF, Wang ML, Chang TJ, Cheng YF, Chiang SH, Chen MF, Liao YT, Chiou SH, Yang DM. (2022, Sep). SARS-CoV-2 vaccines in children and adolescents: Can immunization prevent hospitalization?. Journal of the Chinese Medical Association, 85(9):891-895. doi: 10.1097/JCMA.0000000000000774. .
5. Luo YH, Liang KH, Huang HC, Shen CI, Chiang CL, Wang ML, Chiou SH, Chen YM. (2022, Jun). State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan.. International Journal of Molecular Sciences, 23(13):7037. doi: 10.3390/ijms23137037.
6. Lin CL, Lin YL, Liang KH, Chen LW, Chien CH, Hu CC, Huang TS, Shyu YC, Yeh CT, Chien RN. (2022, Mar). Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan. Clinical Therapeutics, 44(3):403-417.e6. .
7. Liang KH, Chang CC, Wu KS, Yu AL, Sung SY, Lee YY, Liang ML, Chen HH, Fen JJ, Chao ME, Liao YT, Wong TT. (2021, Dec). Notch signaling and natural killer cell infiltration in tumor tissues underlie medulloblastoma prognosis. Scientific Reports, 11(1):23282. MOST 109-2314-B-075-057.
8. Ishola AA, Chien CS, Yang YP, Chien Y, Yarmishyn AA, Tsai PH, Chen JC, HsuPK, Luo YH, Chen YM, Liang KH, Lan YT, Huo TI, Ma HI, Chen MT, Wang ML, Chiou SH. (2021, Nov). Oncogenic circRNA hsa_circ_0000190 modulates EGFR/ERK pathway in promoting NSCLC. Cancer Res. , 1473.2021.
9. Liang KH, Lin YY, Chiang SH, Tsai ET, Lo WL, Wang CL, Wang TY, Sun YC, Kao SY, Wu CH, Hung KF. (2021, Nov). Recent progress of biomarkers in oral cancers. J Chin Med Assoc. , 84(11):987-992.
10. Liang KH, Chen SF, Lin YH, Chu YD, Lin YH, Lai MW, Lin CL, Yeh CT. (2021, Oct). Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma. Biomedicines, 9(11):1539. MOST 109-2314-B-075-057.
11. Liang KH, Lai MW, Lin YH, Chu YD, Lin CL, Lin WR, Huang YH, Wang TH, Chien RN, Hu TH, Yeh CT. (2021, Apr). Plasma interleukin-17 and alphafetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients. BMC Gastroenterology, 17;21(1):177.
12. Liang YJ, Teng W, Chen CL, Sun CP, Teng RD, Huang YH, Liang KH, Chen YW, Lin CC, Su CW, Tao MH, Wu JC. (2021, Mar). Clinical implications on HBV preS/S mutations and the effects of preS2 deletion on mitochondria, liver fibrosis, and cancer development . Hepatology,
13. Hsu CW, Chu YD, Lai MW, Lin CL, Liang KH, Lin YH, Yeh CT. (2021, Jan). Hepatitis B Virus Covalently Closed Circular DNA Predicts Postoperative Liver Cancer Metastasis Independent of Virological Suppression . Cancers, 31;13(3):538.
14. Chen PY, Ho CW, Chen AC, Huang CY, Liu TY, Liang KH. (2020, Dec). Investigating seafood substitution problems and consequences in Taiwan using molecular barcoding and deep microbiome profiling.. Sci Rep. 10(1):21997. doi: 10.1038/s41598-020-79070-y..
15. Yao-Hung Chuang, Wen-Lang Fan, Yu-De Chu, Kung-Hao Liang, Yuan-Ming Yeh, Chien-Chang Chen, Cheng-Hsun Chiu, Ming-Wei Lai (2020, Dec). Whole-Exome Sequencing Identified Novel CLMP Mutations in a Family With Congenital Short Bowel Syndrome Presenting Differently in Two Probands. Frontiers in Genetics, 11:1610, DOI=10.3389/fgene.2020.574943
16. Lai MW, Liang KH, Yeh CT. (2020, Sep). Hepatitis B Virus preS/S Truncation Mutant rtM204I/sW196* Increases Carcinogenesis through Deregulated HIF1A, MGST2, and TGFbi. International Journal of Molecular Sciences, 21(17):E6366. doi: 10.3390/ijms21176366
17. Liang KH, Cheng ML, Lo CJ, Lin YH, Lai MW, Lin WR, Yeh CT. (2020, Jul). Plasma phenylalanine and glutamine concentrations correlate with subsequent hepatocellular carcinoma occurrence in liver cirrhosis patients: an exploratory study. Sci Rep., 10(1):10926.
18. Lin CL, Chien RN, Chu YD, Liang KH, Huang YH, Ke PY, Lin KH, Lin YH, Yeh CT. (2020, Aug). Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression. Hepatol Int., doi: 10.1007/s12072-020-10079-1.
19. Liang KH, Chang TJ, Wang ML, Tsai PH, Lin TH, Wang CT, Yang DM. (2020, Apr). Novel Biosensor Platforms for the Detection of Coronavirus Infection and SARS-CoV-2. J Chin Med Assoc .
20. Yang DM, Chang TJ, Wang ML, Tsai PH, Lin TH, Wang CT, Liang KH. (2020, Apr). Hunting Coronavirus SARS-CoV-2 (2019-nCoV): From Laboratory Testing Back to Basic Research. J Chin Med Assoc, doi: 10.1097/JCMA.0000000000000332.
21. Lin CC, Hsu CW, Chen YC, Chang ML, Liang KH, Lai MW, Lin CL, Chien RN, Lin KH, Yeh CT. (2020, Feb). A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy. Pharmacogenomics J. , 20(1):57-68..
22. Kung-Hao Liang, Yung-Hsiu Lu, Chih-Wei Niu, Sheng-Kai Chang, Yun-Ru Chen, Chih-Ya Cheng, Ting-Rong Hsu, Chia-Feng Yang, Kimitoshi Nakamura & Dau-Ming Niu The Fabry disease-causing mutation, GLA IVS4+919G>A, originated in Mainland China more than 800 years ago. J Hum Genet (2020). https://doi.org/10.1038/s10038-020-0745-7
23. Kuo Sheng Wu, Donald Ming Tak Ho, Shiann Tarng Jou, Alice L. Yu, Huy Minh Tran, Muh Lii Liang, Hsin Hung Chen, Yi Yen Lee, Yi Wei Chen, Shih Chieh Lin, Feng Chi Chang, Min Lan Tsai, Yen Lin Liu, Hsin Lun Lee, Kevin Li Chun Hsieh, Wen Chang Huang, Shian Ying Sung, Che Chang Chang, Chun Austin Changou, Kung Hao Liang, Tsung Han Hsieh, Yun Ru Liu, Meng En Chao, Wan Chen, Shing Shung Chu, Er Chieh Cho, Tai Tong Wong Molecular-Clinical Correlation in Pediatric Medulloblastoma: A Cohort Series Study of 52 Cases in Taiwan. Cancers (Basel). 2020;12(3):653. Published 2020 Mar 11. doi:10.3390/cancers12030653
24. Le PH, Kuo CJ, Hsieh YC, Chen TH, Lin CL, Yeh CT, Liang KH. Ages of hepatocellular carcinoma occurrence and life expectancy are associated with a UGT2B28 genomic variation. BMC Cancer 19, 1190 (2019) doi:10.1186/s12885-019-6409-3
25. Liang, KH., Zhang, P., Lin, CL. Stewart C. Wang, Tsung-Hui Hu Chau-Ting Yeh, Grace L. Su, Morphomic Signatures Derived from Computed Tomography Predict Hepatocellular Carcinoma Occurrence in Cirrhotic Patients. Dig Dis Sci (2020). 65, 2130–2139, https://doi.org/10.1007/s10620-019-05915-w
26. Lin CC, Hsu CW, Chen YC, Chang ML, Liang KH, Lai MW, Lin CL, Chien RN, Lin KH, Yeh CT. A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy. Pharmacogenomics J. 2019 Oct 14. doi: 10.1038/s41397-019-0106-0.
27. Lai MW, Liang KH, Yeh CT. Diverse immune responses to HBV surface epitope variants after vaccine booster in adolescents immunized in infancy. Clin Microbiol Infect. 2019 Feb 13. pii: S1198-743X(19)30049-7. doi: 10.1016/j.cmi.2019.02.003.
28. Chu YD, Lai HY, Pai LM, Huang YH, Lin YH, Liang KH, Yeh CT. The methionine salvage pathway-involving ADI1 inhibits hepatoma growth by epigenetically altering genes expression via elevating S-adenosylmethionine. Cell Death Dis. 2019 Mar 11;10(3):240. doi: 10.1038/s41419-019-1486-4.
29. Liang KH, Ahn SH, Lee HW, Huang YH, Chien RN, Hu TH, Lin KH, Yeh CS, Hsu CW, Lin CL, Pan TL, Ke PY, Chang ML, Yeh CT A novel risk score for hepatocellular carcinoma in Asian cirrhotic patients: a multicentre prospective cohort study.Sci Rep. 2018 Jun 5;8(1):8608
30. Lai MW, Hsu CW, Lin CL, Chien RN, Lin WR, Chang CS, Liang KH, Yeh CT. Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study. Hepatol Int. 2018 Sep;12(5):456-464.
31. Yeh CS, Hsu CW, Liang KH, Chen YC, Lin CL, Chien RN, Hu TH, Lin WR, Lai MW, Chu YD, Yeh CT. Development of a fibrosis index including hepatitis B virus basal core promoter A1762T mutation for pretherapeutic evaluation. J Gastroenterol Hepatol. 2018 Feb 8.33(8):1530-1537.
32. Lin WR, Hsu CW, Yeh CS, Chen YC, Chang ML, Liang KH, Lin CC, Chu YD, Yeh CT. Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2018 Apr;14(2):e54-e63. doi: 10.1111/ajco.12745.
33. Le PH, Liang KH, Chang ML, Hsu CW, Chen YC, Lin CL, Lin WR, Lai MW, Yeh CT. Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment. In Vivo. 2017 Jul-Aug;31(4):723-729.
34. Lin CL, Chien RN, Liang KH, Ke PY, Huang YH, Yeh CT. Intrahepatic HCV RNA Level and Genotype 1 Independently Associate with Hepatic Reticulon 3 Expression. Anticancer Res. 2017 Jun;37(6):2885-2891.
35. Wang TH, Chen CC, Liang KH, Chen CY, Chuang WY, Ueng SH, Chu PH, Huang CG, Chen TC, Hsueh C. A Multivariate Evaluation of Factors Affecting the Quality of Freshly Frozen Tissue Specimens. Biopreserv Biobank. 2017 Aug;15(4):344-349. doi: 10.1089/bio.2016.0104. Epub 2017 May 25.
36. Wang TH, Wu CH, Yeh CT, Su SC, Hsia SM, Liang KH, Chen CC, Hsueh C, Chen CY. Melatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1α inactivation. Oncotarget. 2017 Jul 18;8(47):82280-82293. doi: 10.18632/oncotarget.19316.
37. Liang KH, Yeh CT. O-glycosylation in liver cancer: Clinical associations and potential mechanisms. Liver Research. 2017 1(4):193-196.
38. Liang KH, Yeh TS, Wu RC, Yeh CN, Yeh CT. GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma. Oncol Lett. 2017 Jun;13(6):4215-4223.
39. Tsou YK, Liang KH, Lin WR, Chang HK, Tseng CK, Yeh CT. GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma. Oncotarget. 2017 Mar 16. doi: 10.18632/oncotarget.16253.
40. Huang YH, Liang KH, Chien RN, Hu TH, Lin KH, Hsu CW, Lin CL, Pan TL, Ke PY, Yeh CT. A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients. Sci Rep. 2017 Mar 31;7(1):523. doi: 10.1038/s41598-017-00631-9.
41. Hsu CW, Liang KH, Lin CL, Wang TH, Yeh CT. Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors.BMC Infect Dis. 2017 Jan 5;17(1):9.
42. Yeh CT, Liang KH, Chang ML, Hsu CW, Chen YC, Lin CL, Lin WR, Lai MW. Phenotypic and Genotypic Shifts in Hepatitis B Virus in Treatment-Naive Patients, Taiwan, 2008-2012. Emerg Infect Dis. 2017 May;23(5):820-821.
43. Chen YT, Chen HW, Wu CF, Chu LJ, Chiang WF, Wu CC, Yu JS, Tsai CH, Liang KH, Chang YS, Wu M, Ou Yang WT. Development of a multiplexed LC-MRM/MS method for evaluation of salivary proteins as oral cancer biomarkers. Mol Cell Proteomics. 2017 Feb 24. pii: mcp.M116.064758.
44. Liang KH, Lin CL, Hsu CW, Lai MW, Chien RN, Yeh CT. UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy. Sci Rep. 2016 Sep 26;6:34088. doi: 10.1038/srep34088.
45. Liang KH, Hsu CW, Chang ML, Chen YC, Lai MW, Yeh CT. Peginterferon is superior to nucleos(t)ide analogs for prevention of hepatocellular carcinoma in chronic hepatitis B. Journal of Infectious Diseases 2016 Mar 15;213(6):966-74.
46. Liang KH, Lin CL, Chen SF, Chiu CW, Yang PC, Chang ML, Lin CC, Sung KF, Yeh C, Hung CF, Chien RN, Yeh CT. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.Pharmacogenomics. 2016 Mar;17(4):353-66.
47. Lai MW, Liang KH, Lin WR, Huang YH, Huang SF, Chen TC, Yeh CT  Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. Oncogenesis. 2016 Dec 5;5(12):e273.
48. Chang ML, Liang KH, Ku CL, Lo CC, Cheng YT, Hsu CM, Yeh CT, Chiu CT. Resistin reinforces interferon λ-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotidepolymorphisms. Sci Rep. 2016 Aug 1;6:30799.
49. Lai MW, Lin TY, Liang KH, Lin WR, Yeh CT. Hepatitis B viremia in completely immunized individuals negative for anti-hepatitis B core antibody.  Medicine (Baltimore). 2016 Dec;95(49):e5625.
50. Huang TS, Lin CL, Shyu YC, Yeh CT, Liang KH, Sun CC, Lu MJ, Chien RN. Diabetes, hepatocellular carcinoma, and mortality in hepatitis C-infected patients: a population-based cohort study. J Gastroenterol Hepatol. 2016 Dec 8. doi: 10.1111/jgh.13670.
51. Fu JF, Liang ST, Huang YJ, Liang KH, Yen TH, Liang DC, Shih LY. Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model. Int J Cancer. 2016 Nov 14. doi: 10.1002/ijc.30515.
52. Lin JW, Chang ML, Hsu CW, Chen YC, Liang KH, Huang YH, Lin CC, Yeh CT. Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy. J Med Virol. 2016 Jun 8. doi: 10.1002/jmv.24595.
53. Wang TH, Yu CC, Lin YS, Chen TC, Yeh CT, Liang KH, Shieh TM, Chen CY, Hsueh C. Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition. Oncotarget. 2016 May 26. doi: 10.18632/oncotarget.9635.
54. Lin WR, Chiang JM, Liang KH, Lim SN, Lai MW, Tsou YK, Hsieh TY, Hsu CK, Yeh CT. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy. Medicine. 2016 Apr;95(17):e3487.